

# David Regan of Sona Nanotech provides an update on its agreement with Siva Therapeutics to develop cancer treating therapies

written by InvestorNews | January 27, 2023

In this InvestorIntel interview, [Sona Nanotech Inc.](#)'s (CSE: SONA | OTCQB: SNANF) CEO David Regan provides Tracy Weslosky with an update on Sona's [commercial agreement](#) with Siva Therapeutics to develop therapies for treating cancer. As a strategic supplier of biocompatible gold nanorods to Siva, David discusses why Sona's minimally invasive gold nanorods are the ideal material for use with Siva's cancer tumor therapy system.

David says that the first targeted application will be for colorectal cancer which is the "second most mortal in the world." David also talks about attracting world-class talent to Sona Nanotech's board, including Neil Fraser, past-president of Medtronic Canada, and Walter Strapps, CEO and co-founder of Carver Biosciences Inc. They join Sona Nanotech director Mark Lievonen, former President of Sanofi Pasteur Limited.

To access the full InvestorIntel interview, [click here](#)

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by [clicking here](#).

## About Sona Nanotech Inc.

Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of

various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech's gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

To learn more about Sona Nanotech Inc., [click here](#)

***Disclaimer:*** *Sona Nanotech Inc. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or

any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investorintel.com](mailto:info@investorintel.com).

---

## **Focused on a better future, Siva's cancer tumor therapy system selects Sona's gold nanorod for delivery**

written by InvestorNews | January 27, 2023

Today we are going to talk about a company that is making progress in the targeted treatment of cancers without much of the harmful effects of radiation treatments. Drugs and radiation used in treatment of cancers, while effective at killing tumor cells, cause damage to organs and healthy cells. Traditional

methods of radiation treatment involve non-selective irradiation, damaging the normal tissue surrounding a tumor as well as the cancerous cells. Unfortunately, a lot of these side effects are a necessary evil when dealing with the far more insidious damage that can be done by cancer, but perhaps there is hope a better future.

One company working towards a better future is [Sona Nanotech Inc.](#) (CSE: SONA | OTCQB: SNANF). Sona is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. Their principal business is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech's gold nanorod (GNR) particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

As proof that the Company is advancing its cancer treatment technology, Sona [recently announced](#) that it has entered into an agreement to supply certain gold nanorod material to Siva Therapeutics, Inc., a developer of advanced, 'in-vivo' therapies for treating cancer. Siva Therapeutics' Targeted Hyperthermia™ cancer Therapy (THT) is being developed to be an elegant, safe and effective cancer treatment that generates therapeutic heat within solid tumors using gold nanorods with an infrared light device. THT has multiple beneficial effects on tumors, and it is more selective than chemotherapy, less destructive than radiation, and without the risks of surgical treatment. In addition to being more affordable and more effective, this

technology could deliver faster results than current cancer treatments. Siva has completed successful small animal studies for THT and is preparing to undertake large animal studies in 2023 before beginning human clinical trials for colorectal and possibly other cancer tumors.

Dr. Len Pagliaro, Ph.D., CEO of Siva, commented, "Sona's biocompatible gold nanorods are the ideal material for use with Siva's cancer tumor therapy system. Gold nanorods offer the highest efficiency of energy transfer and Sona's are the only ones we have found globally that don't use toxic CTAB in their manufacturing, assuring safety for 'in-vivo' medical applications." This is probably why Sona will be issued US\$150,000 worth of stock in Siva and the term of the agreement is for ten years. Both positive endorsements for the GNR technology and for Sona.

Other developments going on at Sona include a rapid screening tool to help farmers combat the threat of Bovine Tuberculosis in herds, which is being developed with a consortium of companies as part of a Canada/UK industrial research and development program. It has cost the tax payer [£500 million to control the disease in England](#) in the last 10 years. It is estimated that the costs of bovine TB control will [top £1 billion over the next decade](#), if no action is taken. There is also a concussion test for mild traumatic brain injury that aims to detect a series of biomarkers enabling the screening for mild concussions. The test is intended to detect the presence of GFAP (Glial Fibrillary Acidic Protein), a biological marker associated with concussions, typically released into the bloodstream within minutes of an impact to the head. This could be a tremendous benefit to society as a whole, particularly children. But the capitalist in me is thinking about how much the NFL would pay for a product that could see a player be cleared to resume play in a matter of minutes, or perhaps help the Miami Dolphins team

medical staff keep their jobs by not putting Tua Tagovailoa back out on the field when they shouldn't have.

There's a lot of interesting stuff going on at Sona Nanotech. With a market cap of just C\$7 million, any success could translate well for investors.

---

# David Regan of Sona Nanotech on bringing their rapid saliva Covid-19 test to the market

written by InvestorNews | January 27, 2023

In a recent InvestorIntel interview, Tracy Weslosky spoke with David Regan, CEO of [Sona Nanotech Inc.](#) (CSE: SONA | OTCQB: SNANF) about their rapid saliva COVID-19 test and about why Sona Nanotech is "the gold standard for nanotechnology".

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), David Regan said that Sona Nanotech has developed a unique biocompatible gold nanorod technology that has a wide variety of medical applications. Highlighting the absence of a rapid saliva covid-19 test in the market, David went on to provide an update on Sona Nanotech's partnership with US FDA registered Arlington Scientific to bring Sona's rapid saliva COVID-19 test to market. David also provided an update on the [appointment of two directors](#) to Sona Nanotech's board with backgrounds with a NASDAQ-listed biotech company and Medtronic Canada.

To watch the full interview, [click here](#).

## About Sona Nanotech Inc.

Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech's gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

To learn more about Sona Nanotech Inc., [click here](#).

***Disclaimer:*** *Sona Nanotech Inc. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements.

Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investorintel.com](mailto:info@investorintel.com).

---

## **Jack Lifton interviews David Regan of Sona Nanotech on its breakthrough, gold nanorod, medical technology**

written by InvestorNews | January 27, 2023

In a recent InvestorIntel interview, Jack Lifton spoke with David Regan, CEO of [Sona Nanotech Inc.](https://www.sona-nanotech.com) (CSE: SONA | OTCQB:

SNANF) about how Sona is the world's only producer of gold nanorods that are biocompatible and free from any toxins.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), David Regan provided an update on Sona Nanotech's proprietary gold nanorod technology and went on to highlight the paramount importance of biocompatibility of gold nanorods in medical applications. Having developed the technology that provides stability to gold nanorods to allow them to be shipped worldwide, David went on to explain how Sona is becoming a leader in gold nanorod technology.

To watch the full interview, [click here](#).

#### **About Sona Nanotech Inc.**

Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech's gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

To learn more about Sona Nanotech Inc., [click here](#).

***Disclaimer:*** Sona Nanotech Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investorintel.com](mailto:info@investorintel.com).

---

# David Regan on Sona Nanotech's rapid-result saliva based COVID-19 test

written by InvestorNews | January 27, 2023

In a recent InvestorIntel interview, Chris Thompson spoke with David Regan, CEO of [Sona Nanotech Inc.](#) (CSE: SONA | OTCQB: SNANF) about Sona's [partnership](#) with FDA registered Arlington Scientific to bring its rapid saliva-based COVID-19 test to market.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), David Regan said that Sona Nanotech is a nanotechnology life sciences company with a unique biocompatible gold nanorod platform technology that is free from any toxin. He went on to provide an update on Sona's rapid test development portfolio comprising of a saliva based COVID-19 test and a concussion screening test, the types of which currently don't exist in the market. In the interview, David also provided an update on Sona's research around its gold nanorods for its use in targeted drug delivery and photothermal therapy.

To watch the full interview, [click here](#).

## About Sona Nanotech Inc.

Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business

carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech's gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

To learn more about Sona Nanotech Inc., [click here](#).

**Disclaimer:** Sona Nanotech Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investorintel.com](mailto:info@investorintel.com).